FCCC LOGO Faculty Publications
Kelly AD , Kroeger H , Yamazaki J , Taby R , Neumann F , Yu S , Lee JT , Patel B , Li Y , He R , Liang S , Lu Y , Cesaroni M , Pierce SA , Kornblau SM , Bueso-Ramos CE , Ravandi F , Kantarjian HM , Jelinek J , Issa JP
A CpG island methylator phenotype in acute myeloid leukemia independent of IDH mutations and associated with a favorable outcome
Leukemia. 2017 Oct;31(10) :2011-2019
PMID: 28074068    PMCID: PMC5537054    URL: https://www.ncbi.nlm.nih.gov/pubmed/28074068
Back to previous list
Genetic changes are infrequent in acute myeloid leukemia (AML) compared with other malignancies and often involve epigenetic regulators, suggesting that an altered epigenome may underlie AML biology and outcomes. In 96 AML cases including 65 pilot samples selected for cured/not-cured, we found higher CpG island (CGI) promoter methylation in cured patients. Expanded genome-wide digital restriction enzyme analysis of methylation data revealed a CGI methylator phenotype independent of IDH1/2 mutations we term AML-CGI methylator phenotype (CIMP) (A-CIMP+). A-CIMP was associated with longer overall survival (OS) in this data set (median OS, years: A-CIMP+=not reached, CIMP-=1.17; P=0.08). For validation we used 194 samples from The Cancer Genome Atlas interrogated with Illumina 450k methylation arrays where we confirmed longer OS in A-CIMP (median OS, years: A-CIMP+=2.34, A-CIMP-=1.00; P=0.01). Hypermethylation in A-CIMP+ favored CGIs (OR: CGI/non-CGI=5.21), and while A-CIMP+ was enriched in CEBPA (P=0.002) and WT1 mutations (P=0.02), 70% of cases lacked either mutation. Hypermethylated genes in A-CIMP+ function in pluripotency maintenance, and a gene expression signature of A-CIMP was associated with outcomes in multiple data sets. We conclude that CIMP in AML cannot be explained solely by gene mutations (for example, IDH1/2, TET2), and that curability in A-CIMP+ AML should be validated prospectively.Leukemia advance online publication, 31 January 2017; doi:10.1038/leu.2017.12.
1476-5551 Kelly, A D Kroeger, H Yamazaki, J Taby, R Neumann, F Yu, S Lee, J T Patel, B Li, Y He, R Liang, S Lu, Y Cesaroni, M Pierce, S A Kornblau, S M Bueso-Ramos, C E Ravandi, F Kantarjian, H M Jelinek, J Issa, J-Pj Journal Article England Leukemia. 2017 Jan 31. doi: 10.1038/leu.2017.12.